Client’s Testimonial:
“I'm very happy with my application prep and working with your firm (very professional and knowledgeable, and always prompt in addressing all my queries and concerns). I would definitely recommend you to my colleagues.”
On January 15th, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Biomedical Engineering (Approval Notice).
General Field: Biomedical Engineering
Position at the Time of Case Filing: Research Fellow
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Maryland
Approval Notice Date: January 15th, 2016
Processing Time: 11 days (Premium Processing requested)
Case Summary:
Our client, who was born in India, has an M.S. in Chemical Engineering and a Ph.D. in Biomedical Engineering. Her ensuing career in the multipronged field of biomedical engineering made her a strong candidate for EB-1A (Alien of Extraordinary Ability) approval. When she decided to file an I-140 in the EB-1A category, she hired North America Immigration Law Group (WeGreened.com). Since our client chose to file under Premium Processing, she received her approval after just 11 days.
North America Immigration Law Group demonstrated the influence of our client’s work in part by including recommendation letters contributed by experts in the field. One of our client’s recommenders wrote, “Given the valuable expertise of [Client] in facilitating the research of other scientists in the field, her presence also has a positive impact in general by making the results of her work and exceptional abilities easily available to other American scientists. This is evident from hundreds of downloads of her scientific publications and multiple request from scientists in the field for her print of paper.” When we filed our client’s EB-1A case, her professional achievements included 116 independent citations of her 7 published papers. In the petition, we also emphasized the value of our client’s insights to the scientific community by providing the USCIS with proof of her numerous peer reviews.
In short, we presented the USCIS with a persuasive argument that our client’s work on applying microfluidics to the development of biomimetic in vitro models for studying disease pathogenesis, biomarker detection, pharmaceutical drug transport kinetics, and applications in regenerative medicine is crucial to the United States. We are pleased that the USCIS approved her EB-1A petition and congratulate her on this milestone.